deltatrials
Completed PHASE2 NCT00263276

A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise

Sponsor: AstraZeneca

Conditions Type 2 Diabetes
Interventions dapagliflozin metformin placebo
Updated 7 times since 2017 Last updated: Nov 16, 2016 Started: Dec 31, 2005 Primary completion: Feb 28, 2007 Completion: Feb 28, 2007

Listed as NCT00263276, this PHASE2 trial focuses on Type 2 Diabetes and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
  • Bristol-Myers Squibb
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aguascalientes, Mexico, Akron, United States, Albany, United States, Albuquerque, United States, Anderson, United States, Arkansas City, United States, Augusta, United States, Austin, United States, Bathurst, Canada, Baton Rouge, United States and 133 more location s